DPP4 Assay Kits

Assay Principle

Dipeptidyl peptidase IV (DPP4, also known as CD26) is a serine protease that cleaves N-terminal dipeptides from peptide substrates, most notably rapidly inactivating the incretin hormones GLP-1 and GIP, making it the direct pharmacological target of the "gliptin" class of type 2 diabetes drugs. A DPP4 assay typically uses a fluorometric substrate-cleavage chemistry in which DPP4 hydrolyzes a fluorogenic peptide substrate, releasing a fluorescent product typically read around Ex/Em 360/460 nm. For inhibitor screening applications, the same chemistry is run in the presence and absence of a candidate inhibitor, with the difference in fluorescence signal before and after inhibition used to calculate percent inhibition or IC50 values.

Protocol highlights and purchasing considerations

Protocol Highlights

Kits are validated across a fairly broad range of matrices, including serum, plasma, tissue homogenates, and cultured cells, reflecting DPP4's presence both as a soluble circulating enzyme and as a membrane-bound cell surface protein. Reported sensitivity is commonly in the range of roughly 1 to 4 U/L, with assay times around 70 minutes and modest sample volume requirements. Because DPP4 activity in serum can vary meaningfully with metabolic status and certain disease states, researchers comparing across sample groups should pay attention to whether a kit's detection range comfortably spans both the expected physiological and pathological activity levels in their model.

Assay Kit Purchasing Considerations

For basic DPP4 activity quantification, the fluorometric substrate-cleavage chemistry is broadly consistent across suppliers, so validated sample compatibility and reported sensitivity are the primary differentiators. For inhibitor screening applications specifically, confirming that a kit has been validated with reference gliptin compounds (such as sitagliptin or vildagliptin) as positive controls is a useful due-diligence step, since this provides a benchmark for assay window and reproducibility before screening novel compounds. Given that DPP4 exists both as a soluble enzyme and a cell surface receptor, researchers should also confirm whether a kit is designed to measure enzymatic activity from lysates and biofluids specifically, as opposed to cell surface CD26 expression, which would call for a different (typically antibody-based) detection approach entirely. As with any activity assay, it's good practice to review the full protocol before deciding on a kit, since the manual often reveals practical details, such as incubation times, control requirements, and data analysis steps, that aren't captured in the product summary alone.